Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy for advanced non-small cell lung cancer with liver metastases
ChiCTR2500096580Phase 2Recruiting
- Sponsor
- North China University of Science and Technology Affiliated Hospital
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by North China University of Science and Technology Affiliated Hospital. Primary endpoint: Overall response rate. Started Jan 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500096580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096580.